Pages that link to "Q70358837"
Jump to navigation
Jump to search
The following pages link to Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma (Q70358837):
Displaying 31 items.
- Targeted immunotherapy for pediatric solid tumors (Q26747703) (← links)
- Children's Oncology Group's 2013 blueprint for research: bone tumors (Q27027664) (← links)
- Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice (Q33312280) (← links)
- Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma (Q33597441) (← links)
- Ganglioside GD2 in reception and transduction of cell death signal in tumor cells (Q33613772) (← links)
- GD2 expression in breast cancer. (Q33761830) (← links)
- Trial watch: Immunostimulatory cytokines in cancer therapy (Q33880165) (← links)
- Immunotherapeutic Intervention against Sarcomas (Q34196481) (← links)
- GD2-targeted immunotherapy and radioimmunotherapy (Q34625339) (← links)
- Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness (Q35210792) (← links)
- The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting (Q35832365) (← links)
- GD2 oligosaccharide: target for cytotoxic T lymphocytes (Q36365113) (← links)
- Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. (Q37624276) (← links)
- Anti-GD2 antibody therapy for GD2-expressing tumors (Q37702283) (← links)
- Disialyl gangliosides enhance tumor phenotypes with differential modalities. (Q38024047) (← links)
- Advances in therapy for pediatric sarcomas (Q38217354) (← links)
- Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. (Q39342110) (← links)
- Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults (Q40700335) (← links)
- Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas (Q41636566) (← links)
- Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas (Q41708987) (← links)
- Bone sarcomas: from biology to targeted therapies. (Q41923624) (← links)
- Immune-based therapies for sarcoma (Q41931033) (← links)
- Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors (Q47118215) (← links)
- Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99mTc-methylene diphosphonate parametric imaging with surgical histopathology. (Q54335549) (← links)
- Monoclonal antibodies reactive with human osteogenic cell surface antigens (Q73640190) (← links)
- Pediatric Cancer Immunotherapy: Opportunities and Challenges (Q89287784) (← links)
- Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma (Q90250223) (← links)
- ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway (Q91596604) (← links)
- Immunotherapy in Pediatric Solid Tumors-A Systematic Review (Q92051372) (← links)
- B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2 (Q92978027) (← links)
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy (Q98178304) (← links)